Opinion|Videos|February 3, 2025
Real-World Challenges to Providing Evidence-Based Care for Atopic Dermatitis
Panelists discuss the 2023 American Academy of Allergy, Asthma & Immunology/ American College of Allergy, Asthma & Immunology (AAAAI/ACAAI) Joint Task Force guidelines, highlighting treatment options with strong recommendations and high certainty of evidence, including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib) for atopic dermatitis management.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- 2023 AAAAI/ACAAI Joint Task Force Practice Parameters and Guidelines (Ann Allergy Asthma Immunol 2024;132:274-312).
- Discuss the treatment options with strong recommendations and high certainty of evidence.
- Biologics/monoclonal antibodies: dupilumab, tralokinumab, lebrikizumab
- JAK inhibitors: abrocitinib, baricitinib, upadacitinib
Newsletter
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Phase 3 trial meets primary endpoint for VIASKIN Peanut patch in children aged 4–7 years
2
19-year-old female with painful, purpuric nodules in the phalanges of her fingers
3
Special Report: Rethinking type 1 diabetes through a screening lense
4
FDA approves depemokimab for severe asthma in patients 12 years and older
5